Thomson Reuters Buys GeneGo Biology Solutions

GeneGo’s customers are Pharmaceutical and Biotech companies as well as academic and government institutions such as FDA, NIH and EPA. The company sells software and their data solutions as well as offering outsourced services on a contracted basis for various types of genetic reports. The Meta Core pathway analysis and data mining for gene information , pathways, maps and diseases I am guessing is probably the most used software application and names such as Harvard and the NIH are among a few they list.

Thomson Reuters Healthcare in addition to news has their own diversified area whereby they research and present both very scientific and investor type information. They also have some software available in the support areas for purchase ranging from payer solutions, provider software and clinical trials and perhaps this is where GeneGo may have a link as well in time. BD

From the website:

“GeneGo is a leading provider of data mining & analysis solutions in systems biology. Our data mining tools and databases help to capture and define the underlying biology behind different types of high-throughput experimental data and understand the effects of small molecule drug compounds in human tissues. We provide systems biology solutions for a full range of applications in life science research and drug development, from pre-clinical discovery and NCE applications to clinical trials, covering all aspects of biology and chemistry.”

NEW YORK (GenomeWeb News) – Business information firm Thomson Reuters has bought GeneGo for an undisclosed sum in order to expand its healthcare and life sciences portfolio.

GeneGo, which provides bioinformatics tools for use in drug target selection and validation, biomarker identification, and patient profiling, has become part of Thomson Reuters' Healthcare & Science business segment.

"There is an increasing need for biology content, detailed disease insights, and analytics to support R&D productivity and to enable a more personalized approach to medicine," Jon Brett-Harris, executive vice president at Thomson Reuters, said in a statement Monday.